Six streams in.
One honest picture out.

Because distress, not frequency, is what makes something worth addressing. A desire discrepancy without distress needs education and communication, not a dysfunction label. Starting anywhere else means measuring a person who was never unwell.

It also protects against the most common failure in this field: interpreting avoidance psychologically when it followed pain, or interpreting responsive desire, where wanting arrives after touch begins rather than before, as a deficit. It isn't. It's ordinary.

Antidepressants, antipsychotics, opioids, some blood-pressure medicines, hormonal treatments, prostate and cancer therapies all reshape desire, sensation and orgasm. People are rarely told this clearly, so they conclude the fault is theirs or their partner's.

A dose change eight months ago that lines up precisely with when things shifted is not a coincidence. It is the single most useful fact in the room, and it is routinely missed because nobody asked in the right order. All medication decisions stay with your prescriber. We supply context and chronology, never instructions.

The nervous system does not wait for a sensation and label it afterwards. It predicts, continuously, what the next sensation is likely to mean, and it builds those predictions from what happened before. A body that once had a good reason to brace keeps bracing long after the reason has gone. That is learning working exactly as designed, not a person being difficult.

This is why a person can be objectively safe while their nervous system still anticipates harm, and why the goal is never to convince someone that sensation is harmless. It is to restore agency, choice, control over pace and the freedom to stop. Where history points to trauma, the path leads to an appropriately trained clinician, never to an automated exercise.

They characterise capacity: whether the machinery has room to work. They don't define desire. No hormone concentration determines wanting by itself, which is why leading clinical guidance in this area requires a full biopsychosocial assessment rather than a single test result.

Wearables add what bloods can't: continuity. A blood draw is one morning, while sleep debt, autonomic strain and circadian drift accumulate across weeks and only show their shape over time. Neither is sufficient alone.

These signals also carry information beyond intimacy, and that matters: new, unexplained erectile difficulty is a recognised early cardiovascular signal, particularly in younger men and in diabetes. Sometimes the most important finding here has nothing to do with sex.

Pain followed by avoidance gets a medical and pelvic evaluation before the avoidance is read psychologically. Getting that order wrong is one of the most damaging things that happens to people in this field, and it happens constantly.

Pelvic-floor muscles can be weak, overactive, poorly coordinated or painful. "Tight" and "strong" are not the same thing, and the treatments point in opposite directions. That distinction requires hands and training, not software.

A conventional genetic report reads a gene and tells you something about you. That is not what happens here. Genetics is the last thing consulted and the least authoritative, and it never speaks on its own.

What it contributes is sensitivity: a sense of how strongly your pathways tend to express what the other five streams have already shown. Two people with identical bloods and identical sleep can sit in different places, because the same input does not produce the same expression in every body. Genetic sensitivity is what turns a population-average interpretation into yours. It explains the expression. It does not predict the person.

So it never generates a conclusion, never reaches you as a verdict, and never appears as a variant list to worry over. It weights and contextualises a hypothesis the earlier steps already produced, and where it disagrees with what your body is actually doing, your body wins.

It cannot determine desire, pleasure, behaviour, consent, compatibility, fidelity, orientation or relationship outcomes, and we will not build it to. Findings here describe biological pathways relevant to hormone signalling, vascular health, stress regulation, pain processing and how your body handles a medicine. That is the entire scope, and we would rather state it plainly than imply more.

Advisory and non-diagnostic by design. The system identifies patterns and explains what is worth investigating; diagnosis and treatment stay with your clinician. Sensitive domains remain professional-owned, and coaching layers receive only permitted, non-diagnostic signals. Every dyadic inference passes through practitioner review with an immutable audit trail. The human is not a formality in the workflow. They are the last gate before anything is said to you.

Recalibration matters just as much. A protocol written against last spring's biology is a guess by autumn. At each quarterly or half-yearly review the whole picture is re-read: what moved, what didn't, what stopped being the limiting factor, and what should now take its place. Guidance that never changes was never personalised in the first place.